Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Hatherill

Showing results (191-200 of 222) with videos related to

Pageof 23
Sort By:
Tuberculosis (Edinburgh, Scotland)|April 30, 2017
The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG-induced clinical and immunologic outcomesAndrew D Graustein, David J Horne, Jerry J Fong, et al.
The New England Journal of Medicine|July 12, 2018
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG RevaccinationElisa Nemes, Hennie Geldenhuys, Virginie Rozot, et al.
The New England Journal of Medicine|October 23, 2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosisAmina Jindani, Thomas S Harrison, Andrew J Nunn, et al.
The Lancet. Respiratory Medicine|July 6, 2025
Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trialsRichard G White, Gavin J Churchyard, Katherine C Horton, et al.
Ebiomedicine|March 18, 2025
Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic settingMichele Tameris, Virginie Rozot, Claire Imbratta, et al.
The Lancet. Infectious Diseases|June 30, 2022
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trialMark F Cotton, Shabir A Madhi, Angelique K Luabeya, et al.
Vaccine|June 23, 2015
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adultsAngelique Kany Kany Luabeya, Benjamin M N Kagina, Michele D Tameris, et al.
Vaccine|September 15, 2014
The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responsesBenjamin M N Kagina, Michele D Tameris, Hennie Geldenhuys, et al.
American Journal of Respiratory and Critical Care Medicine|February 20, 2010
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adultsBrian Abel, Michele Tameris, Nazma Mansoor, et al.
The Lancet. Global Health|April 18, 2025
Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trialAngelique Kany Kany Luabeya, Virginie Rozot, Claire Imbratta, et al.
Pageof 23

Showing results (191-200 of 222) with videos related to

Sort By:
Pageof 23
Tuberculosis (Edinburgh, Scotland)|April 30, 2017
The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG-induced clinical and immunologic outcomesAndrew D Graustein, David J Horne, Jerry J Fong, et al.
The New England Journal of Medicine|July 12, 2018
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG RevaccinationElisa Nemes, Hennie Geldenhuys, Virginie Rozot, et al.
The New England Journal of Medicine|October 23, 2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosisAmina Jindani, Thomas S Harrison, Andrew J Nunn, et al.
The Lancet. Respiratory Medicine|July 6, 2025
Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trialsRichard G White, Gavin J Churchyard, Katherine C Horton, et al.
Ebiomedicine|March 18, 2025
Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic settingMichele Tameris, Virginie Rozot, Claire Imbratta, et al.
The Lancet. Infectious Diseases|June 30, 2022
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trialMark F Cotton, Shabir A Madhi, Angelique K Luabeya, et al.
Vaccine|June 23, 2015
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adultsAngelique Kany Kany Luabeya, Benjamin M N Kagina, Michele D Tameris, et al.
Vaccine|September 15, 2014
The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responsesBenjamin M N Kagina, Michele D Tameris, Hennie Geldenhuys, et al.
American Journal of Respiratory and Critical Care Medicine|February 20, 2010
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adultsBrian Abel, Michele Tameris, Nazma Mansoor, et al.
The Lancet. Global Health|April 18, 2025
Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trialAngelique Kany Kany Luabeya, Virginie Rozot, Claire Imbratta, et al.
Pageof 23